Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
NMTC1
MCID: THY109
MIFTS: 57

Thyroid Cancer, Nonmedullary, 1 (NMTC1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 1

About this section

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 1:

Name: Thyroid Cancer, Nonmedullary, 1 57 28 5
Papillary Thyroid Carcinoma 19 28 5 16 71
Familial Nonmedullary Thyroid Cancer, Papillary 57 19 73
Nonmedullary Thyroid Carcinoma, Papillary 57 19 73
Non-Medullary Thyroid Carcinoma 73 71
Papillary Carcinoma of Thyroid 57 73
Thyroid Carcinoma, Papillary 75 12
Papillary Thyroid Cancer 53 33
Nmtc1 57 73
Pact 57 73
Papillary Carcinoma, Diffuse Sclerosing, Thyroid Gland 33
Familial Nonmedullary Thyroid Gland Carcinoma 71
Familial Non-Medullary Thyroid Cancer 73
Cancer, Thyroid, Nonmedullary, Type 1 38
Thyroid Carcinoma, Nonmedullary 1 71
Thyroid Cancer, Non-Medullary, 1 73
Nonmedullary Thyroid Carcinoma 73
Cancer, Thyroid, Nonmedullary 38
Thyroid Papillary Carcinoma 53
Fnmtc 73
Nmtc 73
Ptc 73
Tpc 73

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD11: 33


External Ids:

OMIM® 57 188550
OMIM Phenotypic Series 57 PS188550
MeSH 43 D013964
SNOMED-CT via HPO 69 255029007 3716002
ICD11 33 929788705
UMLS 71 C0238463 C1853488 C3501843 more
Sources

Summaries for Thyroid Cancer, Nonmedullary, 1

About this section

OMIM®: 57 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular (188470), Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100; Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). PTC is characterized by distinctive nuclear alterations including pseudoinclusions, grooves, and chromatin clearing. PTCs smaller than 1 cm are referred to as papillary microcarcinomas. These tumors have been identified in up to 35% of individuals at autopsy, suggesting that they may be extremely common although rarely clinically relevant. PTC can also be multifocal but is typically slow-growing with a tendency to spread to lymph nodes and usually has an excellent prognosis (summary by Bonora et al., 2010). (188550) (Updated 08-Dec-2022)

MalaCards based summary: Thyroid Cancer, Nonmedullary, 1, also known as papillary thyroid carcinoma, is related to papillary thyroid microcarcinoma and thyroid gland anaplastic carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 1 is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and TCA cycle in senescence. The drugs Aztreonam and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are goiter and papillary thyroid carcinoma

GARD: 19 Papillary thyroid carcinoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of certain cells (follicular cells) of the thyroid. Many people with Papillary thyroid carcinoma have no signs or symptoms of the condition. When present, symptoms may include a small lump at the base of the neck, hoarseness, difficulty swallowing, trouble breathing, and pain in the neck or throat. The cause of Papillary thyroid carcinoma is currently unknown.

UniProtKB/Swiss-Prot: 73 A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia: 75 Papillary thyroid cancer or papillary thyroid carcinoma is the most common type of thyroid cancer,... more...
Sources

Related Diseases for Thyroid Cancer, Nonmedullary, 1

About this section

Diseases in the Familial Nonmedullary Thyroid Carcinoma family:

Thyroid Cancer, Nonmedullary, 2 Thyroid Cancer, Nonmedullary, 1
Thyroid Cancer, Nonmedullary, 3 Thyroid Cancer, Nonmedullary, 4
Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1006)
# Related Disease Score Top Affiliating Genes
1 papillary thyroid microcarcinoma 31.8 NKX2-1 BRAF
2 thyroid gland anaplastic carcinoma 31.5 TP53 NKX2-1 MIR222 BRAF
3 struma ovarii 31.3 NKX2-1 BRAF
4 teratoma 31.3 TP53 NKX2-1 H19
5 squamous cell carcinoma 31.2 TP53 NKX2-1 HOTAIR H19 BRAF
6 cystic teratoma 31.1 TP53 NKX2-1
7 lymphatic system disease 31.0 TP53 MIR222 MIR221 MIR146A
8 nkx2-1-related disorders 30.9 SFTA3 NKX2-1
9 differentiated thyroid carcinoma 30.8 NKX2-1 GAS8-AS1 BRAF
10 lung cancer susceptibility 3 30.7 TP53 NKX2-1 LINC-ROR HOTAIR H19 BRAF
11 thyroid carcinoma 30.7 HOTAIR H19 BRAF
12 follicular adenoma 30.7 NKX2-1 MIR222 MIR221 BRAF
13 diffuse large b-cell lymphoma 30.6 MIR222 MIR221 HULC HOTAIR
14 melanoma 30.6 TP53 MIR222 MIR221 LINC-ROR HOTAIR H19
15 skin squamous cell carcinoma 30.6 TP53 HOTAIR BRAF
16 thyroid gland follicular carcinoma 30.6 TP53 NKX2-1 MIR222 MIR221 BRAF
17 thyroid gland cancer 30.5 TP53 NKX2-1 MIR222 MIR221 BRAF
18 thyroid gland papillary carcinoma 30.5 GAS8-AS1 BRAF
19 squamous cell carcinoma, head and neck 30.5 TP53 MIR222 MIR221 HOTAIR H19 BRAF
20 papillary adenocarcinoma 30.5 TP53 NKX2-1 MIR221
21 brain cancer 30.4 TP53 MIR222 MIR221 BRAF
22 thyroid gland medullary carcinoma 30.4 NKX2-1 MIR222 MIR221
23 esophagus squamous cell carcinoma 30.4 LINC-ROR HOTTIP HOTAIR BANCR
24 osteogenic sarcoma 30.4 TP53 HULC HOTTIP HOTAIR H19 BANCR
25 suppression of tumorigenicity 12 30.4 TP53 MIR221 BRAF
26 leukemia, chronic myeloid 30.4 TP53 HULC HOTAIR H19 BRAF
27 glioblastoma 30.4 TP53 MIR222 MIR221 HOTAIR H19 BRAF
28 thyroid gland disease 30.3 TP53 NKX2-1 MIR222 MIR221
29 small cell cancer of the lung 30.3 TP53 NKX2-1 HOTTIP HOTAIR
30 cholangiocarcinoma 30.2 TP53 HULC H19 BRAF
31 ovarian disease 30.2 TP53 MIR222 MIR221 MIR146A
32 oral squamous cell carcinoma 30.1 MIR221 MIR146A HOTAIR H19
33 myeloma, multiple 30.0 TP53 SFTA3 NKX2-1 MIR221 HOTAIR H19
34 bone inflammation disease 30.0 MIR222 MIR221 MIR146A
35 ovarian epithelial cancer 30.0 HULC HOTAIR H19
36 nasopharyngeal carcinoma 29.9 TP53 MIR146A LINC-ROR HULC HOTAIR H19
37 pancreatic ductal adenocarcinoma 29.9 TP53 MIR222 MIR221 MIR146A HOTTIP HOTAIR
38 esophageal cancer 29.8 TP53 MIR222 MIR221 MIR146A HULC HOTAIR
39 gallbladder cancer 29.8 TP53 LINC-ROR HOTAIR H19 BRAF
40 high grade glioma 29.8 TP53 MIR221 LINC-ROR HULC HOTTIP HOTAIR
41 renal cell carcinoma, nonpapillary 29.8 TP53 NKX2-1 MIR222 MIR221 MIR146A LINC-ROR
42 bladder cancer 29.8 TP53 MIR222 MIR221 HULC HOTAIR H19
43 glioma 29.7 TP53 MIR222 MIR221 HULC HOTTIP HOTAIR
44 pancreatic cancer 29.6 TP53 MIR222 MIR221 MIR146A LINC-ROR HULC
45 gastric cancer 29.5 TP53 MIR222 MIR221 LINC-ROR HULC HOTTIP
46 hepatocellular carcinoma 29.5 TP53 NKX2-1 MIR222 MIR221 MIR146A LINC-ROR
47 multicentric papillary thyroid carcinoma 11.4
48 thyroid cancer, nonmedullary, 3 11.4
49 thyroid carcinoma, papillary, with papillary renal neoplasia 11.3
50 facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome 11.2

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 1:



Diseases related to Thyroid Cancer, Nonmedullary, 1
Sources

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 1

About this section

Human phenotypes related to Thyroid Cancer, Nonmedullary, 1:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 goiter 30 HP:0000853
2 papillary thyroid carcinoma 30 HP:0002895
3 non-medullary thyroid carcinoma 30 HP:0040198

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neoplasia:
nonmedullary thyroid carcinoma (papillary)
goiter, multinodular

Clinical features from OMIM®:

188550 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 1

About this section

Drugs for Thyroid Cancer, Nonmedullary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5742832
2 Anti-Infective Agents Phase 4
3 Anti-Bacterial Agents Phase 4
4 Antibiotics, Antitubercular Phase 4
5
Prazosin Approved Phase 3 19216-56-9 4893
6
Zoledronic acid Approved Phase 3 118072-93-8 68740
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8 Neurotransmitter Agents Phase 3
9 Adrenergic Antagonists Phase 3
10 Adrenergic alpha-Antagonists Phase 3
11 Adrenergic alpha-1 Receptor Antagonists Phase 3
12 Adrenergic Agents Phase 3
13 Antihypertensive Agents Phase 3
14
Iodine Approved, Investigational Phase 2 7553-56-2 807
15
Calcium carbonate Approved, Investigational Phase 2 471-34-1
16
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
17
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
18
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
19
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
20
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
21
Vemurafenib Approved Phase 2 918504-65-1 42611257
22
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
23
Nivolumab Approved Phase 1, Phase 2 946414-94-4
24
Fluorouracil Approved Phase 1, Phase 2 51-21-8 3385
25
Eflornithine Approved, Withdrawn Phase 1, Phase 2 70052-12-9 3009
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
Tremelimumab Approved, Investigational Phase 2 745013-59-6
28
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760
29
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
30
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
31
Entrectinib Approved, Investigational Phase 2 1108743-60-7 25141092
32
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
33
Pralsetinib Approved, Investigational Phase 1, Phase 2 2097132-94-8 129073603
34
Trametinib Approved Phase 2 871700-17-3 11707110
35
Panitumumab Approved, Investigational Phase 2 339177-26-3
36
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
37
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
39
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
40
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 155817456
41
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
42
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 2 67-97-0, 1406-16-2 5280795 10883523
43
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
44
Ornithine Approved, Nutraceutical Phase 1, Phase 2 3184-13-2, 70-26-8 6262
45
Lysine Approved, Nutraceutical Phase 1, Phase 2 56-87-1 5962
46
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
47
Cadexomer iodine Experimental Phase 2 94820-09-4
48
Spartalizumab Investigational Phase 2 1935694-88-4
49
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2 91976570
50 Vitamins Phase 2

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent Unknown status NCT01057563 Phase 4
2 A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube. Terminated NCT03158116 Phase 4 Inhaled Aztreonam
3 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
4 CSP #563 - Prazosin and Combat Trauma PTSD (PACT) Completed NCT00532493 Phase 3 prazosin
5 Non-small Cell Lung Cancer Study US75 (Z-PACT) Completed NCT00086268 Phase 3 zoledronic acid;Taxotere;Carboplatin
6 Pediatric Asthma Controller Trial (PACT) Completed NCT00272506 Phase 3 inhaled corticosteroid;long-acting beta2-agonist
7 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
8 Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients Completed NCT00630214 Phase 2
9 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
10 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
11 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
12 Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer Completed NCT02138214 Phase 2
13 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
14 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
15 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
16 An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine Completed NCT01286753 Phase 2 Vemurafenib
17 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
18 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
19 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
20 The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services. Completed NCT00207493 Phase 1, Phase 2
21 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
22 A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Recruiting NCT04731467 Phase 1, Phase 2 CM-24 and Nivolumab - Dose Escalation;CM-24 and Nivolumab - Expansion;CM-24, Nivolumab, and Nab paclitaxel - Expansion;CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
23 A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer Recruiting NCT05500508 Phase 1, Phase 2 AMXT1501;DFMO
24 Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer Recruiting NCT04544111 Phase 2 Trametinib;Dabrafenib;PDR001
25 Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy Recruiting NCT02593175 Phase 2 Carboplatin;Paclitaxel
26 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
27 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements Active, not recruiting NCT02568267 Phase 2 Entrectinib
28 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Active, not recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
29 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
30 A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer Active, not recruiting NCT02876107 Phase 2 Carboplatin;Paclitaxel
31 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
32 Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer Terminated NCT02408887 Phase 2
33 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Terminated NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
34 Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study Unknown status NCT00103155 Phase 1
35 A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients Unknown status NCT03469011 Phase 1 Imatinib Oral Tablet
36 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
37 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
38 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
39 A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors Completed NCT00451880 Phase 1 XL281;famotidine
40 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
41 Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and Completed NCT03470259 Phase 1 IV adminstration of EMI-137
42 Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma Recruiting NCT04389281 Phase 1
43 A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT) Active, not recruiting NCT02791334 Phase 1 LY3300054;Ramucirumab;Abemaciclib;Merestinib;LY3321367
44 Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma Unknown status NCT03889769
45 Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0? Unknown status NCT04336696
46 The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma Unknown status NCT04076514
47 Differences Protein Expression in Papillary Thyroid Carcinoma Unknown status NCT02814032
48 99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study Unknown status NCT00984191
49 Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound Unknown status NCT00929318
50 Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma Unknown status NCT01417442 Early Phase 1

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 1

Sources

Genetic Tests for Thyroid Cancer, Nonmedullary, 1

About this section

Genetic tests related to Thyroid Cancer, Nonmedullary, 1:

# Genetic test Affiliating Genes
1 Papillary Thyroid Carcinoma 28
2 Thyroid Cancer, Nonmedullary, 1 28 NKX2-1
Sources

Anatomical Context for Thyroid Cancer, Nonmedullary, 1

About this section

Organs/tissues related to Thyroid Cancer, Nonmedullary, 1:

MalaCards : Thyroid, Lymph Node, Breast, Lung, Myeloid, Colon, Skin
Sources

Publications for Thyroid Cancer, Nonmedullary, 1

About this section

Articles related to Thyroid Cancer, Nonmedullary, 1:

(show top 50) (show all 15461)
# Title Authors PMID Year
1
A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. 53 62 57 5
19176457 2009
2
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 53 62 57 5
15181070 2004
3
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 53 62 57 5
12670889 2003
4
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. 53 62 57
18000091 2008
5
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 53 62 5
17785355 2007
6
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 53 62 5
16772349 2006
7
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 53 62 5
16174717 2005
8
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 53 62 5
15998781 2005
9
BRAF T1796A transversion mutation in various thyroid neoplasms. 53 62 5
15001635 2004
10
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. 53 62 57
12970315 2003
11
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. 53 62 57
11443191 2001
12
Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. 53 62 57
10487693 1999
13
Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. 53 62 57
9192845 1997
14
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. 53 62 57
1569189 1992
15
The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. 62 57
22586128 2012
16
The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. 62 57
20350937 2010
17
Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. 62 57
20628519 2010
18
Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. 62 57
20001717 2009
19
Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. 62 57
17956956 2008
20
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 53 5
17488796 2007
21
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 62 5
17374713 2007
22
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 53 5
15687339 2005
23
Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. 62 57
15546898 2005
24
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 53 5
15356022 2004
25
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 53 5
15126572 2004
26
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 53 5
14602780 2003
27
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). 62 57
12679489 2003
28
Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. 62 57
12574236 2003
29
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. 62 57
11861385 2002
30
Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. 62 57
11747322 2001
31
Familial non-medullary thyroid cancer in Iceland. 62 57
11303513 2001
32
Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. 62 57
11158026 2001
33
RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. 62 57
10980597 2000
34
Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. 62 57
10946873 2000
35
The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. 62 57
10720057 2000
36
Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium. 62 57
10372725 1999
37
A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. 62 57
9837827 1998
38
Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. 62 57
9814501 1998
39
Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. 62 57
7632152 1995
40
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. 53 57
8187085 1994
41
Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. 62 57
2400971 1990
42
Simultaneous presentation of papillary carcinoma of thyroid in a father and son. 62 57
6831161 1983
43
Familial occurrence of papillary thyroid carcinoma. 62 57
7214311 1980
44
Codon-specific translation reprogramming promotes resistance to targeted therapy. 5
29925953 2018
45
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 5
28854169 2017
46
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 5
25079330 2014
47
Copper is required for oncogenic BRAF signalling and tumorigenesis. 5
24717435 2014
48
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 5
24670642 2014
49
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 5
24512911 2014
50
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 5
23685455 2013
Sources

Variations for Thyroid Cancer, Nonmedullary, 1

About this section

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

5 (show all 11)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NKX2-1, SFTA3 NM_001079668.3(NKX2-1):c.1106C>T (p.Ala369Val) SNV Pathogenic
 487553 rs537209983 GRCh37: 14:36986583-36986583
GRCh38: 14:36517378-36517378
2 TP53 NM_000546.6(TP53):c.1118del (p.Lys373fs) DEL Pathogenic
 1052297 GRCh37: 17:7572991-7572991
GRCh38: 17:7669673-7669673
3 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Pathogenic
 13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
4 LIG4 NM_206937.2(LIG4):c.1673A>C (p.Gln558Pro) SNV Likely Pathogenic
 620632 rs751409106 GRCh37: 13:108861944-108861944
GRCh38: 13:108209596-108209596
5 KRAS NM_004985.5(KRAS):c.445A>T (p.Arg149Ter) SNV Likely Pathogenic
 1327505 GRCh37: 12:25378553-25378553
GRCh38: 12:25225619-25225619
6 RINT1 NM_021930.6(RINT1):c.1107+1G>T SNV Likely Pathogenic
 653869 rs200989342 GRCh37: 7:105190613-105190613
GRCh38: 7:105550166-105550166
7 RINT1 NM_021930.6(RINT1):c.1021C>G (p.Leu341Val) SNV Likely Pathogenic
 946956 rs151055286 GRCh37: 7:105190526-105190526
GRCh38: 7:105550079-105550079
8 PCM1 NM_006197.4(PCM1):c.2935C>T (p.Gln979Ter) SNV Uncertain Significance
 225430 rs1085307084 GRCh37: 8:17823587-17823587
GRCh38: 8:17966078-17966078
9 NKX2-1, SFTA3 NM_001079668.3(NKX2-1):c.463+4A>G SNV Uncertain Significance
 930341 rs1881201369 GRCh37: 14:36988186-36988186
GRCh38: 14:36518981-36518981
10 ATM, C11orf65 NM_000051.4(ATM):c.8560C>T (p.Arg2854Cys) SNV Uncertain Significance
 142147 rs201958469 GRCh37: 11:108216611-108216611
GRCh38: 11:108345884-108345884
11 PALB2 NM_024675.4(PALB2):c.2147A>G (p.Asn716Ser) SNV Uncertain Significance
 232654 rs148335539 GRCh37: 16:23641328-23641328
GRCh38: 16:23630007-23630007

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 1:

73
# Symbol AA change Variation ID SNP ID
1 NKX2-1 p.Ala339Val VAR_075769 rs537209983

Copy number variations for Thyroid Cancer, Nonmedullary, 1 from CNVD:

6 (show all 16)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13343 1 1 124300000 Chromosomal rearrangement Papillary thyroid carcinoma
2 13804 1 1 60900000 Chromosomal rearrangement Papillary thyroid carcinoma
3 19995 1 152394403 152431233 Translate TPM3 Papillary thyroid carcinoma
4 42899 10 42100000 53300000 Chromosomal rearrangement Papillary thyroid carcinoma
5 44673 10 61218526 61336824 Translate CCDC6 Papillary thyroid carcinoma
6 91970 15 37900000 47600000 Copy number FGF7 Papillary thyroid carcinoma
7 95418 15 76100000 86900000 Copy number AKAP13 Papillary thyroid carcinoma
8 96732 15 92330402 92376057 Translate GOLGA5 Papillary thyroid carcinoma
9 106730 17 1 11200000 Copy number USP6 Papillary thyroid carcinoma
10 140387 2 197100000 209100000 Copy number TRAK2 Papillary thyroid carcinoma
11 148729 2 83700000 91000000 Amplification TMSB10 Papillary thyroid carcinoma
12 166063 3 1 14700000 Chromosomal rearrangement Papillary thyroid carcinoma
13 166395 3 101910849 101950501 Translate TFG Papillary thyroid carcinoma
14 194280 5 139000000 143100000 Copy number EIF4EBP3 Papillary thyroid carcinoma
15 219438 7 126900000 158821424 Chromosomal rearrangement Papillary thyroid carcinoma
16 232143 8 112100000 146364022 Amplification Papillary thyroid cancer
Sources

Expression for Thyroid Cancer, Nonmedullary, 1

About this section
Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 1.
Sources

Pathways for Thyroid Cancer, Nonmedullary, 1

About this section

Pathways related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
miRNAs involved in DNA damage response 74
10.63 TP53 MIR222 MIR221
2
TCA cycle in senescence 74
9.96 TP53 BRAF
Sources

GO Terms for Thyroid Cancer, Nonmedullary, 1

About this section

Biological processes related to Thyroid Cancer, Nonmedullary, 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of glial cell proliferation GO:0060253 9.7 TP53 MIR146A
2 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.67 MIR222 MIR221 MIR146A
3 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.65 MIR222 MIR221 MIR146A
4 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.63 MIR222 MIR221 MIR146A
5 negative regulation by host of viral genome replication GO:0044828 9.51 MIR222 MIR221
6 positive regulation of axon regeneration GO:0048680 9.46 MIR222 MIR221 BRAF
7 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.43 MIR222 MIR221
8 negative regulation of interleukin-21 production GO:0032705 9.4 MIR222 MIR221
9 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.37 MIR222 MIR221
10 positive regulation of Schwann cell migration GO:1900149 9.32 MIR222 MIR221
11 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.26 MIR222 MIR221
12 negative regulation of cell adhesion molecule production GO:0060354 9.13 MIR222 MIR221 MIR146A
13 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 8.8 MIR222 MIR221 MIR146A
Sources

Sources for Thyroid Cancer, Nonmedullary, 1

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....